2019
Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension
Shelburne NJ, Parikh KS, Chiswell K, Shaw LK, Sivak J, Arges K, Tomfohr J, Velazquez EJ, Kisslo J, Samad Z, Rajagopal S. Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension. The American Journal Of Cardiology 2019, 124: 1298-1304. PMID: 31481176, DOI: 10.1016/j.amjcard.2019.07.026.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntihypertensive AgentsEchocardiographyExercise TestFemaleFollow-Up StudiesHeart VentriclesHumansMaleMiddle AgedNorth CarolinaPrognosisPulmonary Arterial HypertensionRetrospective StudiesSeverity of Illness IndexStroke VolumeSurvival RateVentricular Function, RightYoung AdultConceptsTricuspid annular plane systolic excursionPulmonary arterial hypertensionRV global longitudinal strainRV systolic pressureRight ventricular functionGlobal longitudinal strainArterial hypertensionSystolic pressureVentricular functionSevere pulmonary arterial hypertensionAnnular plane systolic excursionLongitudinal strainPAH-specific therapyManagement of patientsRight atrial areaMid-RVPAH therapyCause mortalityEchocardiographic parametersClinical responseEchocardiographic variablesSystolic excursionWalk distanceEchocardiographic assessmentAtrial area
2010
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial
Nilsson KR, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJ, Califf RM, Velazquez EJ. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart 2010, 96: 838. PMID: 20406769, DOI: 10.1136/hrt.2009.180182.Peer-Reviewed Original ResearchConceptsRhythm control strategyAcute Myocardial Infarction trialMyocardial Infarction trialAtrial fibrillationMyocardial infarctionRate control strategyEarly mortalityAnti-arrhythmic drug therapyTreatment of AFPeri-infarct periodIncidence of strokeManagement of patientsRisk of deathLate mortalityPatient populationDrug therapyCox modelPatientsMortalityInfarctionStrokeValsartanTrialsDeathDays
2008
Emerging Role of Myocardial Perfusion Imaging to Evaluate Patients for Cardiac Resynchronization Therapy††Conflicts of interest: Dr. Garcia has an ownership interest in and serves as a consultant and advisory board member for Syntermed, Inc., Atlanta, Georgia. Dr. Garcia also receives royalties from the sale of clinical software that was used as part of this research. Dr. Borges-Neto and Dr. Trimble have received research support from the Duke-Medtronic Strategic Alliance, which funded some of the studies reviewed in this report.
Trimble MA, Borges-Neto S, Velazquez EJ, Chen J, Shaw LK, Pagnanelli R, Garcia EV, Iskandrian AE. Emerging Role of Myocardial Perfusion Imaging to Evaluate Patients for Cardiac Resynchronization Therapy††Conflicts of interest: Dr. Garcia has an ownership interest in and serves as a consultant and advisory board member for Syntermed, Inc., Atlanta, Georgia. Dr. Garcia also receives royalties from the sale of clinical software that was used as part of this research. Dr. Borges-Neto and Dr. Trimble have received research support from the Duke-Medtronic Strategic Alliance, which funded some of the studies reviewed in this report. The American Journal Of Cardiology 2008, 102: 211-217. PMID: 18602524, DOI: 10.1016/j.amjcard.2008.03.043.Peer-Reviewed Original ResearchConceptsCardiac resynchronization therapyMechanical dyssynchronyElectrical dyssynchronyMyocardial perfusionSignificant heart failure symptomsTomographic myocardial perfusion imagingLV functional improvementHeart failure symptomsLV systolic dysfunctionSevere LV dysfunctionSelection of patientsManagement of patientsLV mechanical dyssynchronyLeft ventricular dyssynchronyMyocardial perfusion imagingCurrent selection criteriaLV dysfunctionSystolic dysfunctionEchocardiographic measuresResynchronization therapyVentricular dyssynchronyCardiac resynchronizationClinical statusLV remodelingFailure symptoms
2000
Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design
Pfeffer M, McMurray J, Leizorovicz A, Maggioni A, Rouleau J, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers M, Velazquez E, Califf R, Investigators* F. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. American Heart Journal 2000, 140: 727-750. PMID: 11054617, DOI: 10.1067/mhj.2000.108832.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IIAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilCause of DeathDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationHumansMulticenter Studies as TopicMyocardial InfarctionOdds RatioPatient SelectionProportional Hazards ModelsRandomized Controlled Trials as TopicResearch DesignSample SizeTetrazolesValineValsartanConceptsAngiotensin II receptor blockersII receptor blockersAcute myocardial infarctionMyocardial infarctionReceptor blockersVentricular dysfunctionHeart failureAngiotensin II receptor blocker valsartanEnzyme inhibitorsMajor nonfatal cardiovascular eventsAcute Myocardial Infarction trialAngiotensin-converting enzyme inhibitorDose of captoprilMultiple practice patternsNonfatal cardiovascular eventsUse of valsartanMyocardial Infarction trialReceptor blocker valsartanHigh-risk patientsLeft ventricular dysfunctionParallel-group studyRenin-angiotensin systemManagement of patientsCombination of captoprilLong-term treatment